Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rabe

Showing results (541-550 of 646) with videos related to

Pageof 65
Sort By:
Chest|February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUSSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|December 9, 2024
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trialDave Singh, Christopher E Brightling, Klaus F Rabe, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 1, 1999
[Asthma therapy in children and adults. Recommendations of the German Respiratory League of the German Society of Pneumology]R Wettengel, D Berdel, D Hofmann, et al.
Allergy|July 7, 2020
RNA-seq-based profiling of extracellular vesicles in plasma reveals a potential role of miR-122-5p in asthmaThomas Bahmer, Susanne Krauss-Etschmann, Dominik Buschmann, et al.
The European Respiratory Journal|September 11, 2017
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineJadwiga A Wedzicha, Peter M A Calverley, Richard K Albert, et al.
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The European Respiratory Journal|January 13, 2018
Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?Kevin C Wilson, Jerry A Krishnan, Pawel Sliwinski, et al.
Respiratory Research|January 8, 2017
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
The European Respiratory Journal|March 17, 2017
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineJadwiga A Wedzicha, Marc Miravitlles, John R Hurst, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
Pageof 65

Showing results (541-550 of 646) with videos related to

Sort By:
Pageof 65
Chest|February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUSSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|December 9, 2024
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trialDave Singh, Christopher E Brightling, Klaus F Rabe, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 1, 1999
[Asthma therapy in children and adults. Recommendations of the German Respiratory League of the German Society of Pneumology]R Wettengel, D Berdel, D Hofmann, et al.
Allergy|July 7, 2020
RNA-seq-based profiling of extracellular vesicles in plasma reveals a potential role of miR-122-5p in asthmaThomas Bahmer, Susanne Krauss-Etschmann, Dominik Buschmann, et al.
The European Respiratory Journal|September 11, 2017
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineJadwiga A Wedzicha, Peter M A Calverley, Richard K Albert, et al.
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The European Respiratory Journal|January 13, 2018
Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?Kevin C Wilson, Jerry A Krishnan, Pawel Sliwinski, et al.
Respiratory Research|January 8, 2017
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
The European Respiratory Journal|March 17, 2017
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineJadwiga A Wedzicha, Marc Miravitlles, John R Hurst, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
Pageof 65